Sulfonylurea News and Research

RSS
IQWiG dossier assessment finds no added benefit of lixisenatide

IQWiG dossier assessment finds no added benefit of lixisenatide

Study finds that triple therapy corrects two core defects in type 2 diabetes

Study finds that triple therapy corrects two core defects in type 2 diabetes

Patients with type2 diabetes, renal impairment have less hypoglycemia with JANUVIA compared to sulfonylurea

Patients with type2 diabetes, renal impairment have less hypoglycemia with JANUVIA compared to sulfonylurea

Linagliptin significantly reduces blood glucose levels in T2D patients with moderate to severe renal impairment

Linagliptin significantly reduces blood glucose levels in T2D patients with moderate to severe renal impairment

Sanofi presents positive phase 3 data for GLP-1 receptor for type 2 diabetes

Sanofi presents positive phase 3 data for GLP-1 receptor for type 2 diabetes

Bristol-Myers Squibb and AstraZeneca announce top line results of Phase 4 SAVOR-TIMI-53 clinical trial of Onglyza

Bristol-Myers Squibb and AstraZeneca announce top line results of Phase 4 SAVOR-TIMI-53 clinical trial of Onglyza

Researchers to study benefits, side effects of four widely used therapies in adults with type 2 diabetes

Researchers to study benefits, side effects of four widely used therapies in adults with type 2 diabetes

Baylor Endocrine Center seeks volunteers to compare long-term benefits and risks of diabetes drugs

Baylor Endocrine Center seeks volunteers to compare long-term benefits and risks of diabetes drugs

EPAC2 and diabetes: an interview with Dr. Hussain, Johns Hopkins University

EPAC2 and diabetes: an interview with Dr. Hussain, Johns Hopkins University

Merck, Pfizer sign collaboration agreement for development and commercialization of ertugliflozin

Merck, Pfizer sign collaboration agreement for development and commercialization of ertugliflozin

Invokana tablets receive FDA approval to treat adults with type 2 diabetes

Invokana tablets receive FDA approval to treat adults with type 2 diabetes

No added benefit from linagliptin in patients with type 2 diabetes

No added benefit from linagliptin in patients with type 2 diabetes

Lilly, Boehringer Ingelheim announce top-line results from empagliflozin Phase III trials on T2D

Lilly, Boehringer Ingelheim announce top-line results from empagliflozin Phase III trials on T2D

Diabetes tests: an interview with Dr. Danielle Stowasser

Diabetes tests: an interview with Dr. Danielle Stowasser

Sulfonylureas risk vs metformin points to clear first-line diabetes choice

Sulfonylureas risk vs metformin points to clear first-line diabetes choice

Metformin more effective than sulfonylurea in controlling type 2 diabetes

Metformin more effective than sulfonylurea in controlling type 2 diabetes

GW to evaluate effectiveness of glucose-lowering drugs against type 2 diabetes

GW to evaluate effectiveness of glucose-lowering drugs against type 2 diabetes

Lilly, Boehringer Ingelheim announce availability of My Well Planner for adults with type 2 diabetes

Lilly, Boehringer Ingelheim announce availability of My Well Planner for adults with type 2 diabetes

PhaseBio commences Glymera Phase 2b study in type 2 diabetes

PhaseBio commences Glymera Phase 2b study in type 2 diabetes

Lilly, Boehringer Ingelheim receive FDA approval for Tradjenta sNDA to treat type 2 diabetes

Lilly, Boehringer Ingelheim receive FDA approval for Tradjenta sNDA to treat type 2 diabetes